Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 24%
Buy 18%
Hold 53%
Sell 6%
Strong Sell 0%

Bulls say

Zimmer Biomet Holdings is the market leader in orthopedic reconstructive implants and surgical equipment, with a dominant share of the US, Europe, and Japan markets. The recent acquisitions of Centerpulse and Biomet have strengthened the company's position in the market. Despite a more complicated first quarter, the company beat expectations on sales, margins, and EPS. While there are some short-term challenges, such as the CFO's departure, factors such as strong product innovation and a direct sales model transformation suggest long-term growth potential for the company. As a result, I have a positive outlook on Zimmer Biomet Holdings' stock.

Bears say

Zimmer Biomet Holdings is facing a number of challenges that are impacting its outlook for the future. Investments in Paragon 28 and Monogram are expected to continue, but with a pause on mergers and acquisitions and potential slowdown in sales due to the continued impact of the pandemic, the company's growth potential is limited. The recent spin-off of its dental and spine businesses also indicates a potential shift in focus and strategy, which could affect overall performance. The company's financials show mixed results, with a projected 2% revenue growth in 2026 and 2027, and a slight decline in EPS from $9.11 prior to $9.71 in 2028.

ZBH has been analyzed by 17 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 18% recommend Buy, 53% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 17 analysts, ZBH has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.